Endometriosis Treatment Industry Set for a Steady 3% CAGR from 2019 to 2030 | FMI Insights

Endometriosis Treatment Industry

The global Endometriosis Treatment Industry is poised for remarkable expansion, driven by a surge in investments by key stakeholders and a growing awareness among women. According to the latest data, the market was valued at US$ 2.8 billion in 2018, and it is anticipated to maintain a steady Compound Annual Growth Rate (CAGR) of approximately 3% over the forecast period (2019-2030).

The escalation in the prevalence of endometriosis, a condition affecting millions of women worldwide, is generating an upswing in the demand for effective treatment options. The industry is placing a strong emphasis on pioneering therapeutically-advanced solutions for endometriosis, thereby fostering market growth over the projected period.

Leading players in the industry are making substantial strides in the development of cutting-edge scientific and clinical therapeutic agents, as well as the introduction of new products within the global endometriosis treatment market. This concerted effort by industry leaders is expected to be a driving force behind future market expansion.

Request a Sample Copy of the Report Now.
https://www.futuremarketinsights.com/reports/sample/rep-gb-3870

Key Takeaways of Endometriosis Treatment Industry Study

  • Based on drug, oral contraceptives contributed maximum value share to the global endometriosis treatment Industry in 2018, owing to high preference for them as a first-line therapy for patients without contraindications, and efficacy in preventing recurrence of pelvic pain and endometriosis lesions.
  • High treatment efficacy and acceptance with low risk are expected to result in notable share of hormonal therapy in the treatment type.
  • The hospital pharmacies and retail pharmacies segments, collectively, hold above 60% of value share to the endometriosis treatment market, owing to the high patient pool in hospitals and visiting retail pharmacies.
  • Europe captured a notable revenue share of 37% in 2018, and is expected to be the most lucrative region in the global endometriosis treatment market during the forecast period.
  • Increasing government expenditure for high growth of the medical industry in emerging economies in the Asian region is expected to drive the growth of the endometriosis treatment market across this region.

Multiple New Indications – Imperative Strategy for Market Players

Increasing the introduction of endometriosis drugs with multiple new indications is a major factor responsible for intense competition among market players. Several companies are focusing on launching new endometriosis treatment options to increase their product sales and expand their market share. For example, in July 2018, AbbVie Inc. introduced a new innovative product – Orilissa™ (elagolix) tablets, a gonadotropin-releasing hormone (GnRH) receptor antagonist for the management of moderate to severe pain associated with endometriosis, in the U.S. market.

Methodology Details Just a Click Away!
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-3870

What else is in the report?

Future Market Insights (FMI) offers a unique perspective and actionable insights on the endometriosis treatment market in its latest study, presenting historical demand assessment of 2014-2018 and projections for the period of 2019-2030, based on drug (oral contraceptives, progestins, NSAIDs, GnRH analogues, LNR-IUDs, and others), treatment type (hormonal therapy and pain management), and distribution channel (hospital pharmacies, retail pharmacies, drugstores, and e-Commerce), across seven key regions of the world.

Market segmentation

The global endometriosis treatment market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

Drug:

  • Oral Contraceptives
  • Progestins
  • NSAIDs
  • GnRH Analogues
  • LNR-IUDs
  • Others

Treatment Type:

  • Hormonal Therapy
  • Pain Management

Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drugstores
  • e-Commerce

Access Exclusive Market Insights – Purchase Now!
https://www.futuremarketinsights.com/checkout/3870

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:      

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs | YouTube

About the Author

Nikhil Kaitwade

Associate Vice President at Future Market Insights, Inc. has over a decade of experience in market research and business consulting. He has successfully delivered 1500+ client assignments, predominantly in Automotive, Chemicals, Industrial Equipment, Oil & Gas, and Service industries.
His core competency circles around developing research methodology, creating a unique analysis framework, statistical data models for pricing analysis, competition mapping, and market feasibility analysis. His expertise also extends wide and beyond analysis, advising clients on identifying growth potential in established and niche market segments, investment/divestment decisions, and market entry decision-making.
Nikhil holds an MBA degree in Marketing and IT and a Graduate in Mechanical Engineering. Nikhil has authored several publications and quoted in journals like EMS Now, EPR Magazine, and EE Times.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may also like these